Abbott (ABT) Stock
Diversified global healthcare company with devices and nutrition. Here's the price, business snapshot, and what's worth knowing about Abbott in September 2026.
Abbott Laboratories (ABT) is a diversified global healthcare company operating across diagnostics, medical devices, nutritionals and branded generic pharmaceuticals. With a market capitalisation around $221.98B, Abbott supplies a mix of recurring-revenue products — from diagnostic systems and cardiovascular devices to glucose-monitoring products and infant nutrition — that can offer relative resilience across economic cycles. Investors should note its exposure to regulatory approvals, reimbursement policies and competition from large medtech and pharmaceutical peers, plus currency and supply-chain risks in international markets. Abbott invests in R&D and product upgrades, which can support long-term growth but also requires ongoing capital. The company has historically returned cash to shareholders, yet past distributions do not guarantee future payments. This summary is for general, educational purposes and is not personalised investment advice; individuals should assess suitability, consult up-to-date sources, and consider seeking regulated financial advice before investing.
Why It’s Moving
Abbott gets a lift from fresh FDA approval and steady analyst confidence
- Abbott received U.S. FDA approval for its TactiFlex Duo Ablation Catheter, a regulatory win that expands its cardiovascular device lineup and supports growth in a high-demand heart-rhythm market.
- The company has also been getting attention for recent product momentum, including a new infant formula launch and clearance for Libre Duo 10 Day, reinforcing its mix of medtech and diabetes-care growth drivers.
- Analyst sentiment stayed constructive this week, with brokerages maintaining a Moderate Buy view and signaling that expectations remain anchored in Abbott’s earnings resilience rather than a single catalyst.
Abbott gets a lift from fresh FDA approval and steady analyst confidence
- Abbott received U.S. FDA approval for its TactiFlex Duo Ablation Catheter, a regulatory win that expands its cardiovascular device lineup and supports growth in a high-demand heart-rhythm market.
- The company has also been getting attention for recent product momentum, including a new infant formula launch and clearance for Libre Duo 10 Day, reinforcing its mix of medtech and diabetes-care growth drivers.
- Analyst sentiment stayed constructive this week, with brokerages maintaining a Moderate Buy view and signaling that expectations remain anchored in Abbott’s earnings resilience rather than a single catalyst.
When is the next earnings date for Abbott (ABT)?
Abbott Laboratories’ next earnings report is typically expected around October 14–21, 2026, with the most likely date currently estimated at October 21, 2026. It should cover Q3 2026 results. The company has not formally confirmed the date yet, so the timing remains based on its historical reporting pattern.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Abbott's stock with a target price of $125.82, indicating growth potential.
Financial Health
Abbott is performing well with strong profits and cash flow, indicating solid financial stability.
Dividend
Abbott's dividend yield of 2.43% provides a decent return for income-seeking investors. If you invested $1000, you would be paid $24.30 a year in dividends (based on the last 12 months).
Why You’ll Want to Watch This Stock
Stable revenue mix
Recurring sales from diagnostics and devices can support steadier cash flows, though performance will vary and is not guaranteed.
Global market reach
A broad international footprint offers growth opportunities but brings currency, regulatory and supply-chain exposure to watch.
Product innovation focus
Ongoing R&D and device upgrades can drive long-term growth, yet new product development faces regulatory and competitive hurdles.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.